Screener
Ligand Pharmaceuticals LGND Contract revenue — Total revenues and income
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Ligand Pharmaceuticals’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000886163-26-000044
| Line item | Three months ended / June 30, 2026 | Three months ended / June 30, 2025 | Six months ended / June 30, 2026 | Six months ended / June 30, 2025 |
|---|---|---|---|---|
| Income from financial royalty assets | 10,670 | 6,313 | 20,697 | 12,215 |
| Total royalties | 48,032 | 36,397 | 90,990 | 63,886 |
| Captisol | 7,978 | 8,287 | 16,632 | 21,747 |
| Contract revenue and income | ||||
| Contract revenue | 2,683 | 1,926 | 2,793 | 6,310 |
| Income | 5,000 | 1,017 | 5,000 | 1,017 |
| Total contract revenue and income | 7,683 | 2,943 | 7,793 | 7,327 |
| Total revenues and income | $63,693 | $47,627 | $115,415 | $92,960 |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Ligand Pharmaceuticals's contract revenue — total revenues and income?
- Ligand Pharmaceuticals (LGND) reported contract revenue — total revenues and income of $2.68M in Q2 2026.
- How has Ligand Pharmaceuticals's contract revenue — total revenues and income changed year-over-year?
- Ligand Pharmaceuticals's contract revenue — total revenues and income increased by 39.3% year-over-year, from $1.93M to $2.68M.
- What is the long-term trend for Ligand Pharmaceuticals's contract revenue — total revenues and income?
- Over 2 years (2022 to 2025), Ligand Pharmaceuticals's contract revenue — total revenues and income has grown at a 88.4% compound annual growth rate (CAGR), from $18.84M to $66.87M.
- What does contract revenue — total revenues and income mean?
- This metric represents the aggregate financial inflows generated from the contract-based business segment, encompassing both recurring service fees and non-recurring milestone payments. It serves as a primary indicator of the company's ability to monetize its proprietary technologies and development partnerships. Monitoring this figure helps investors assess the scale and performance of the company's contract-driven revenue streams.
Ask your AI about Ligand Pharmaceuticals's contract revenue — total revenues and income.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude